SCHEMBL8682105

SCHEMBL8682105

CNC(=O)OC1CCCN1C

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.35
ACHE P22303 5/20 0.34
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
BCHE P06276 2/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNA5 P30532 1/20 0.32
CHRNA7 P36544 1/20 0.32
CHRNA4 P43681 1/20 0.32
L3MBTL3 Q96JM7 1/20 0.32
CHRM3 P20309 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8680907 0.81 EPHX1 (0.53) SMN1; SMN2ACHEOPRM1OPRD1OPRK1
SCHEMBL3905171 0.79 SMN1; SMN2 (0.38) SMN1; SMN2CYP2D6CHRNB2CHRNA5CHRNA7
SCHEMBL688825 0.79 SMN1; SMN2 (0.38) SMN1; SMN2CYP2D6CHRNB2CHRNA5CHRNA7
SCHEMBL688697 0.79 SMN1; SMN2 (0.38) SMN1; SMN2CYP2D6CHRNB2CHRNA5CHRNA7
SCHEMBL8680813 0.77 ALDH1A1 (0.48) CHRM1SMN1; SMN2ACHECYP2D6CHRM3
SCHEMBL8704065 0.77 SMN1; SMN2 (0.37) SMN1; SMN2CYP2D6CHRNB2CHRNA5CHRNA7
Hydrochloric Acid SCHEMBL21801417 0.77 SMN1; SMN2 (0.40) CHRM1SMN1; SMN2CYP2D6CHRM3
SCHEMBL8683160 0.74 SMN1; SMN2 (0.35) CHRM1SMN1; SMN2BCHECHRNB2CHRNA5
SCHEMBL9330153 0.74 EPHX1 (0.38) OPRM1BCHECHRNB2CHRNA4
SCHEMBL6695503 0.73 CHRM2 (0.39) CHRM1CYP2D6CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5843983-A Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use SANKYO COMPANY, LIMITED (JP) 1998-12-01 US disclosed
EP-0844000-A1 Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis SANKYO COMPANY LIMITED (JP) 1998-05-27 EP disclosed
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP disclosed